Prognostic significance of creatine kinase release after percutaneous coronary intervention.

Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation (2011) 1.78

Successful treatment of ischemic dysfunction of the sinus node with thrombolytic therapy: a case report. Korean J Intern Med (2006) 0.75

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet (2008) 3.27

Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61

Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: meta-analysis and meta-regression. Int J Cardiol (2013) 1.94

[Prognostic significance of the elevation of the indices of myocardial damage after percutaneous coronary revascularization interventions]. Ital Heart J Suppl (2002) 1.90

Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J (2005) 1.80

Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J (2003) 1.76

Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study. JACC Cardiovasc Interv (2010) 1.54

Early invasive versus selectively invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: impact of age. Catheter Cardiovasc Interv (2014) 1.43

Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention (2014) 1.41

[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation]. G Ital Cardiol (Rome) (2012) 1.40

Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. Circulation (2002) 1.38

Emergency percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by out-of-hospital cardiac arrest: early and medium-term outcome. Am Heart J (2008) 1.02

Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J (2005) 0.99

Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med (Hagerstown) (2008) 0.97

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA (2002) 0.87

Clinical characteristics and outcome of diabetic patients with acute myocardial infarction. Data from the BLITZ-1 study. Ital Heart J (2005) 0.87

1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv (2009) 0.86

The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. Am Heart J (2005) 0.84

Prognostic value of isolated troponin I elevation after percutaneous coronary intervention. Circ Cardiovasc Interv (2010) 0.83

The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement. Eur Heart J Acute Cardiovasc Care (2012) 0.83

Causes of death in patients ≥75 years of age with non-ST-segment elevation acute coronary syndrome. Am J Cardiol (2013) 0.80

Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Intern Emerg Med (2014) 0.80

Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. J Cardiovasc Med (Hagerstown) (2008) 0.79

[Bivalirudin as an anticoagulant during percutaneous coronary interventions in acute coronary syndromes: strengths and doubts]. Rev Esp Cardiol (2011) 0.78

Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: implications on optimisation of timing of treatment from the CARESS-in-AMI trial. Int J Cardiol (2010) 0.78

Prasugrel and ticagrelor: is there a winner? J Cardiovasc Med (Hagerstown) (2014) 0.77

[Percutaneous coronary interventions in elderly patients: clinical indications and adjunctive medical treatment. The Italian Drug Evaluation in Angioplasty (IDEA) study]. G Ital Cardiol (Rome) (2006) 0.77

Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. Drugs (2015) 0.77

How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial? Int J Cardiol (2011) 0.76

[Systematic primary angioplasty in acute myocardial infarction: quality cannot be improvised]. Ital Heart J Suppl (2003) 0.75

Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets (2014) 0.75

[Myocardial infarction redefined based on the consensus document of the ESC/ACC]. Ital Heart J Suppl (2002) 0.75

[The EUROMAX study]. G Ital Cardiol (Rome) (2014) 0.75

[Diagnosis and treatment of non-ST-elevation acute coronary syndromes. Common clinical lessons and a few differences between the ESC and the ACC/AHA guidelines published in 2007]. G Ital Cardiol (Rome) (2008) 0.75

Cardiogenic shock developing in the coronary care unit in patients with ST-elevation myocardial infarction. J Cardiovasc Med (Hagerstown) (2008) 0.75

Cystatin C and risk of mortality among patients undergoing percutaneous coronary intervention. EuroIntervention (2015) 0.75

Delayed profound thrombocytopenia after abciximab administration for coronary stenting in acute coronary syndrome. Case reports and review of the literature. Ital Heart J (2005) 0.75

[European 2014 guidelines on the diagnosis and treatment of acute pulmonary embolism: underlying the importance of "patient-centered" clinical assessment as well as of new management and therapeutic approaches]. G Ital Cardiol (Rome) (2015) 0.75

Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy. J Cardiovasc Med (Hagerstown) (2008) 0.75

Antiplatelet and Anticoagulation Treatment in patients with thrombocytopenia. Curr Pharm Des (2016) 0.75

Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry. J Cardiovasc Med (Hagerstown) (2017) 0.75

Massive left ventricular ischemia in a patient with anterior ST elevation myocardial infarction and anomalous origin of the circumflex artery. J Cardiovasc Med (Hagerstown) (2016) 0.75

[Predictive elements and prevention of myocardial damage during angioplasty/stenting]. Ital Heart J Suppl (2002) 0.75

Non-ST-elevation acute coronary syndrome in chronic kidney disease: prognostic implication of an early invasive strategy. Minerva Cardiol Angiol (2022) 0.75

[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. G Ital Cardiol (Rome) (2010) 0.75

Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J (2005) 0.75

Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Curr Med Res Opin (2011) 0.75

Antiplatelet therapy for patients with stable ischemic heart disease and baseline thrombocytopenia: ask the hematologist. Platelets (2013) 0.75

[MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction]. G Ital Cardiol (Rome) (2009) 0.75

[Treatment of acute coronary syndrome in older adults and high-risk patients."When the going gets tough…"]. Recenti Prog Med (2015) 0.75